You just read:

FDA Grants Breakthrough Therapy Designation for Debiopharm's Novel Chemo-radio Sensitizer Debio 1143 for Front-line Treatment of Head & Neck Cancer

News provided by

Debiopharm International SA

27 Feb, 2020, 14:17 GMT